$MGNX News

Macrogenics Q1 EPS $(0.58) Beats $(0.65) Estimate, Sales $20.775M Beat $15.050M Estimate

MacroGenics Enters Into Expanded Royalty Purchase Agreement With Sagard In Exchange For Capped Royalty Interest On Future Global Net Sales Of ZYNYZ

Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6

MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble

MacroGenics Says FDA Removes Partial Clinical Hold On Phase 2 LINNET Study Of Lorigerlimab, Investigational, Bispecific DART Molecule That Targets PD-1 And CTLA-4

MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

MacroGenics shares are trading higher after the company reported better-than-expected Q4 financial results. Also, Barclays maintained its Overweight rating and raised its price target from $3 to $4.

MacroGenics shares are trading higher after the company reported better-than-expected Q4 financial results. Also, Barclays maintained its Overweight rating and raised its price target from $3 to $4.

Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4

Macrogenics Q4 EPS $(0.22) Beats $(0.48) Estimate, Sales $41.227M Beat $22.643M Estimate

Why Is MacroGenics Stock Sinking Tuesday?

Reported Earlier, MacroGenics Pauses Enrollment In LINNET Study As FDA Imposes Partial Clinical Hold Following Serious Safety Events In Gynecologic Cancer Patients

January 2026's Top Penny Stocks To Watch

Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes

FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children

MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

Results: MacroGenics, Inc. Confounded Analyst Expectations With A Surprise Profit

MacroGenics: Q3 Earnings Snapshot

Macrogenics Q3 EPS $0.27 Beats $(0.58) Estimate, Sales $72.839M Beat $14.700M Estimate

MacroGenics (MGNX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?